Journal
DIABETES TECHNOLOGY & THERAPEUTICS
Volume 14, Issue 6, Pages 505-507Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2011.0248
Keywords
-
Categories
Funding
- NIMHD NIH HHS [U54 MD007588] Funding Source: Medline
Ask authors/readers for more resources
Background: Changes in hemoglobin A1c (A1C), weight, and total daily insulin dose (TDD) were investigated following initiation of insulin U-500 (U500) alone or as part of a basal/bolus insulin (BBI) regimen. Subjects and Methods: Records of patients with type 2 diabetes who were prescribed U500 were retrospectively reviewed. Logistic regression analysis was used to investigate relationships between changes in MC and use of U500 alone or as BBI. Results: Twelve patients were identified as using U500 alone (n = 2) or in combination with long-acting (LAI) (n = 7) or rapid-acting (RAI) (n = 3) insulin. Reductions in A1C (9.5% at baseline vs. 7.7% at 6-9 months, P<0.0001) and increases in weight (128.8+/-32.7 vs. 131.5+/-31.3 kg, P<0.014) and TDD (260+/-111 to 333+/-106 units/day, P<0.0002) were observed. Concurrent use of LAI or RAI with U500 did not predict improvements in A1C. Conclusions: U500 resulted in improvements in A1C and weight gain and increased TDD when used alone or as part of combination insulin therapy. Further investigations to define the optimal use of U500 are recommended.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available